Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Hoffmann-La Roche |
---|---|
Information provided by: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00048061 |
This study will compare the efficacy and safety of different treatment regimens of oral Bonviva tablets in women with post-menopausal osteoporosis.
Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.
Condition | Intervention | Phase |
---|---|---|
Post-Menopausal Osteoporosis |
Drug: ibandronate [Bonviva/Boniva] |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind Study Comparing the Effect of Monthly Versus Daily Treatment With Oral Bonviva on Lumbar Bone Mineral Density in Women With Osteoporosis |
Enrollment: | 1609 |
Study Completion Date: | April 2005 |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: ibandronate [Bonviva/Boniva]
2.5mg po daily
|
2: Experimental |
Drug: ibandronate [Bonviva/Boniva]
100mg po monthly on a single day
|
3: Experimental |
Drug: ibandronate [Bonviva/Boniva]
100mg po monthly over 2 consecutive days
|
4: Experimental |
Drug: ibandronate [Bonviva/Boniva]
150mg po monthly
|
Ages Eligible for Study: | 55 Years to 80 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Clinical Trials | Hoffmann-La Roche, +1 973 235 5000 |
Responsible Party: | Hoffmann-La Roche ( Clinical Trials, Study Director ) |
Study ID Numbers: | BM16549 |
Study First Received: | October 24, 2002 |
Last Updated: | April 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00048061 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Ibandronic acid Musculoskeletal Diseases Osteoporosis, Postmenopausal Osteoporosis |
Bone Density Conservation Agents Bone Diseases, Metabolic Bone Diseases Menopause |
Ibandronic acid Musculoskeletal Diseases Physiological Effects of Drugs Osteoporosis, Postmenopausal Osteoporosis |
Bone Density Conservation Agents Bone Diseases, Metabolic Bone Diseases Pharmacologic Actions |